Abstract:What's new? Resistance to targeted and immune therapies limits the benefits of current treatments in melanoma. This study provides evidence for a new combined approach in targeting BRAF inhibitor‐resistant melanoma. Pharmacological inhibition of the resistance‐inducing Rho/MRTF pathway using CCG‐257081 enhanced the response to PD1/PDL1 blockade in vivo. Moreover, anti‐PD1/CCG‐257081 co‐treatment increased infiltration of CD8+ T cells and B cells into the tumor microenvironment and reduced tumor‐associated macrophage infiltration. CCG‐257081 emerges as a potential new anti‐resistance agent that can improve the response to immune checkpoint inhibitors in advanced melanoma. Metastatic cutaneous melanoma is a fatal skin cancer. Resistance to targeted and immune therapies limits the benefits of current treatments. Identifying and adding anti‐resistance agents to current treatment protocols can potentially improve clinical responses. Myocardin‐related transcription factor (MRTF) is a transcriptional coactivator whose activity is indirectly regulated by actin and the Rho family of GTPases. We previously demonstrated that development of BRAF inhibitor (BRAFi) resistance frequently activates the Rho/MRTF pathway in human and mouse BRAFV600E melanomas. In clinical trials, pretreatment with BRAFi reduces the benefit of immune therapies. We aimed to test the efficacy of concurrent treatment with our MRTF pathway inhibitor CCG‐257081 and anti‐PD1 in vivo and to examine its effects on the melanoma immune microenvironment. Because MRTF pathway activation upregulates the expression of immune checkpoint inhibitor genes/proteins, we asked whether CCG‐257081 can improve the response to immune checkpoint blockade. CCG‐257081 reduced the expression of PDL1 in BRAFi‐resistant melanoma cells and decreased surface PDL1 levels on both BRAFi‐sensitive and ‐resistant melanoma cells. Using our recently described murine vemurafenib‐resistant melanoma model, we found that CCG‐257081, in combination with anti‐PD1 immune therapy, reduced tumor growth and increased survival. Moreover, anti‐PD1/CCG‐257081 co‐treatment increased infiltration of CD8+ T cells and B cells into the tumor microenvironment and reduced tumor‐associated macrophages. Here, we propose CCG‐257081 as an anti‐resistance and immune therapy‐enhancing anti‐melanoma agent.

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models Through Sustained Antitumor Immunity

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

RAS/MAPK Activation is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials

Dual MAPK Inhibition Triggers Pro-inflammatory Signals and Sensitizes BRAF V600E Glioma to T Cell-Mediated Checkpoint Therapy

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation-Positive Melanoma: Patient Selection and Perspectives

In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways

Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review)

Cnsc-25. Concurrent Immune Checkpoint Blockade Enhances The Survival Benefit Of Clinically Relevant Mapk Pathway Inhibitors In A T Cell-Dependent Manner

The potential of BRAF-targeted therapy combined with immunotherapy in melanoma

Inhibition of the Rho/MRTF pathway improves the response of BRAF‐resistant melanoma to PD1/PDL1 blockade

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment

Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action